PTC Therapeutics Inc
NASDAQ: PTCT · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
PTC Therapeutics Inc (PTCT) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2004 | 2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $38.97M | $43.97M | $44.15M | $13.07M | $151.90M | $333.22M | $368.04M | $269.35M | $391.65M | $1.12B | $1.62B | $2.21B | $1.94B | $1.71B | $1.90B | $1.71B | $2.91B |
| Cash & equivalents | $6.78M | $10.96M | $28.43M | $2.73M | $15.41M | $315.24M | $338.93M | $231.67M | $191.25M | $227.59M | $288.03M | $208.81M | $773.38M | $279.83M | $594.00M | $779.71M | $984.65M |
| Current assets | — | — | $33.05M | $4.60M | $145.02M | $323.57M | $355.95M | $261.29M | $249.06M | $320.86M | $779.28M | $1.23B | $773.38M | $693.78M | $1.22B | $1.37B | $2.27B |
| Total liabilities | $4.36M | $5.57M | $282.75M | $32.27M | $15.36M | $34.75M | $69.57M | $149.76M | $235.22M | $768.50M | $1.03B | $1.73B | $1.94B | $2.05B | $2.71B | $2.80B | $3.12B |
| Current liabilities | $4.13M | $4.65M | $43.15M | $28.16M | $13.13M | $32.48M | $45.39M | $49.62M | $82.05M | $166.80M | $235.86M | $277.33M | $509.35M | $406.24M | $603.10M | $580.98M | $968.43M |
| Long-term debt | $205000.00 | $804000.00 | $4.55M | $439000.00 | $0.00 | $0.00 | $94.61M | $98.22M | $144.97M | $141.35M | $293.86M | $309.14M | $281.89M | $571.72M | $1.90B | $2.11B | $2.03B |
| Shareholder equity | $34.61M | $38.40M | $-238.60M | $-19.19M | $136.54M | $298.47M | $298.47M | $119.58M | $156.44M | $350.73M | $594.33M | $481.98M | $1.44M | $-347.09M | $-818.55M | $-1.10B | $-205.31M |
| Retained earnings | — | — | $-250.61M | $-277.22M | $-328.80M | $-422.55M | $-593.00M | $-735.11M | $-814.11M | $-938.92M | $-1.19B | $-1.63B | $-2.10B | $-2.66B | $-3.28B | $-3.65B | $-2.96B |
| Accounts receivable | — | — | $1.24M | $1.01M | $958000.00 | $4.45M | $11.09M | $24.93M | $40.39M | $67.91M | $55.54M | $69.93M | $110.45M | $155.61M | $160.82M | $158.55M | $181.62M |
| Inventory | — | — | — | — | $0.00 | $0.00 | $0.00 | $1.70M | $10.75M | $16.12M | $19.29M | $18.70M | $15.86M | $21.81M | $30.58M | $23.19M | $79.65M |
| Goodwill | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $132.99M | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M |
Frequently asked questions
What is PTC Therapeutics Inc's revenue?
PTC Therapeutics Inc's trailing twelve-month revenue is $827.11M, and consensus projects about $2.58B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is PTCT?
In its most recent fiscal year, PTCT ran a gross margin of 95.85%, an operating margin of 49.49%, and a net margin of 39.44%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does PTCT generate?
PTCT produced $702.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is PTCT's balance sheet healthy?
PTCT holds $984.65M in cash and equivalents against $2.03B in long-term debt, on $-205.31M of shareholder equity. That debt is best read against the cash flow the business throws off each year.